Invictus MD Strategies (Invictus MD Strategies) Tax Provision : $1.42 Mil (TTM As of Oct. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Invictus MD Strategies Tax Provision?

Invictus MD Strategies's tax provision for the three months ended in Oct. 2019 was $0.30 Mil. Its tax provision for the trailing twelve months (TTM) ended in Oct. 2019 was $1.42 Mil.

Invictus MD Strategies Tax Provision Historical Data

The historical data trend for Invictus MD Strategies's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invictus MD Strategies Tax Provision Chart

Invictus MD Strategies Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Tax Provision

0.37

0.67

1.25

Invictus MD Strategies Quarterly Data
	Jan15	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19
Tax Provision	Get a 7-Day Free Trial															0.11	1.08	0.26	-0.22	0.30

Invictus MD Strategies Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Oct. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.42 Mil.

Invictus MD Strategies (Invictus MD Strategies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Invictus MD Strategies Corp (OTCPK:IVITF) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

595 Burrard Street, 16th floor, Vancouver, BC, CAN, V7X 1J1

Website

http://www.invictus-md.com

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.